The efficacy and safety of neoadjuvant treatment with the PD-1 inhibitor for locally advanced colorectal cancer: a meta-analysis
ObjectiveTo systematically evaluate the efficacy and safety of PD-1 inhibitors in neoadjuvant therapy for locally advanced colorectal cancer (LACRC).MethodRetrieved from PubMed, Embase, and the Cochrane Library, all relevant studies about PD-1 inhibitors for neoadjuvant treatment of LACRC were colle...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-12-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1416943/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846145855848972288 |
|---|---|
| author | Yan Yu Yan Yu Lin Huang Lin Huang Rong Yan Rong Yan Min Jiang Min Jiang Shuang-Jiao Li Shuang-Jiao Li Wang-Dong Fan Wang-Dong Fan |
| author_facet | Yan Yu Yan Yu Lin Huang Lin Huang Rong Yan Rong Yan Min Jiang Min Jiang Shuang-Jiao Li Shuang-Jiao Li Wang-Dong Fan Wang-Dong Fan |
| author_sort | Yan Yu |
| collection | DOAJ |
| description | ObjectiveTo systematically evaluate the efficacy and safety of PD-1 inhibitors in neoadjuvant therapy for locally advanced colorectal cancer (LACRC).MethodRetrieved from PubMed, Embase, and the Cochrane Library, all relevant studies about PD-1 inhibitors for neoadjuvant treatment of LACRC were collected from inception to 31 December 2023. The efficacy was assessed by the rate of pathological complete response (PCR), clinical complete response (CCR), and major pathological response (MPR), and the safety was evaluated by the incidence of all adverse effects (TRAEs). Subgroup analysis was conducted by experimental design, types of PD-1 inhibitors, and disease types.ResultA total of 803 patients were included in 21 studies. The results of the meta-analysis showed that the PCR rate of PD-1 inhibitors in the treatment of LACRC was 54% (95% CI: 43%–65%, P<0.05); the CCR of anti-PD-1 was 40% (95% CI: 26%–54%, P<0.05); the MPR was 66% (95% CI: 56%–76%, P<0.05); and the irAEs was 27% (95% CI: 17%–37%, P<0.05). Subgroup analysis showed that the PCRs in prospective studies and retrospective studies were 49% (95% CI: 32%–66%, P<0.05) and 57% (95% CI: 42%–73%, P<0.05), respectively. Among the 803 patients, 619 (77%) were diagnosed with rectal cancer (RC), and the PCR and MPR were 49% and 65%, respectively; 184 (23%) were diagnosed with colorectal cancer (CRC), and the PCR and MPR were both 67%. In our meta-analysis, types of PD-1 inhibitors, including sintilimab, toripalimab, camrelizumab, avelumab, pembrolizumab, and tislelizumab, and patients who received PD-1 inhibitors alone or in combination achieved good PCR rates.ConclusionNeoadjuvant therapy combined with a PD-1 inhibitor has a favorable PCR and relatively low incidences of irAEs for patients with LACRC, suggesting that this regimen including a PD-1 inhibitor is significantly effective and sufficiently safe. |
| format | Article |
| id | doaj-art-c56e54cc8e9b42ffa9396891d76e0cb1 |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-c56e54cc8e9b42ffa9396891d76e0cb12024-12-02T05:10:13ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2024-12-011410.3389/fonc.2024.14169431416943The efficacy and safety of neoadjuvant treatment with the PD-1 inhibitor for locally advanced colorectal cancer: a meta-analysisYan Yu0Yan Yu1Lin Huang2Lin Huang3Rong Yan4Rong Yan5Min Jiang6Min Jiang7Shuang-Jiao Li8Shuang-Jiao Li9Wang-Dong Fan10Wang-Dong Fan11West China School of Public Health, Sichuan University, Chengdu, Sichuan, ChinaWest China Fourth Hospital, Sichuan University, Chengdu, Sichuan, ChinaWest China School of Public Health, Sichuan University, Chengdu, Sichuan, ChinaWest China Fourth Hospital, Sichuan University, Chengdu, Sichuan, ChinaWest China School of Public Health, Sichuan University, Chengdu, Sichuan, ChinaWest China Fourth Hospital, Sichuan University, Chengdu, Sichuan, ChinaWest China School of Public Health, Sichuan University, Chengdu, Sichuan, ChinaWest China Fourth Hospital, Sichuan University, Chengdu, Sichuan, ChinaWest China School of Public Health, Sichuan University, Chengdu, Sichuan, ChinaWest China Fourth Hospital, Sichuan University, Chengdu, Sichuan, ChinaWest China School of Public Health, Sichuan University, Chengdu, Sichuan, ChinaWest China Fourth Hospital, Sichuan University, Chengdu, Sichuan, ChinaObjectiveTo systematically evaluate the efficacy and safety of PD-1 inhibitors in neoadjuvant therapy for locally advanced colorectal cancer (LACRC).MethodRetrieved from PubMed, Embase, and the Cochrane Library, all relevant studies about PD-1 inhibitors for neoadjuvant treatment of LACRC were collected from inception to 31 December 2023. The efficacy was assessed by the rate of pathological complete response (PCR), clinical complete response (CCR), and major pathological response (MPR), and the safety was evaluated by the incidence of all adverse effects (TRAEs). Subgroup analysis was conducted by experimental design, types of PD-1 inhibitors, and disease types.ResultA total of 803 patients were included in 21 studies. The results of the meta-analysis showed that the PCR rate of PD-1 inhibitors in the treatment of LACRC was 54% (95% CI: 43%–65%, P<0.05); the CCR of anti-PD-1 was 40% (95% CI: 26%–54%, P<0.05); the MPR was 66% (95% CI: 56%–76%, P<0.05); and the irAEs was 27% (95% CI: 17%–37%, P<0.05). Subgroup analysis showed that the PCRs in prospective studies and retrospective studies were 49% (95% CI: 32%–66%, P<0.05) and 57% (95% CI: 42%–73%, P<0.05), respectively. Among the 803 patients, 619 (77%) were diagnosed with rectal cancer (RC), and the PCR and MPR were 49% and 65%, respectively; 184 (23%) were diagnosed with colorectal cancer (CRC), and the PCR and MPR were both 67%. In our meta-analysis, types of PD-1 inhibitors, including sintilimab, toripalimab, camrelizumab, avelumab, pembrolizumab, and tislelizumab, and patients who received PD-1 inhibitors alone or in combination achieved good PCR rates.ConclusionNeoadjuvant therapy combined with a PD-1 inhibitor has a favorable PCR and relatively low incidences of irAEs for patients with LACRC, suggesting that this regimen including a PD-1 inhibitor is significantly effective and sufficiently safe.https://www.frontiersin.org/articles/10.3389/fonc.2024.1416943/fullprogrammed cell death protein-1PD-1locally advanced colorectal cancerneoadjuvant therapymeta-analysis |
| spellingShingle | Yan Yu Yan Yu Lin Huang Lin Huang Rong Yan Rong Yan Min Jiang Min Jiang Shuang-Jiao Li Shuang-Jiao Li Wang-Dong Fan Wang-Dong Fan The efficacy and safety of neoadjuvant treatment with the PD-1 inhibitor for locally advanced colorectal cancer: a meta-analysis Frontiers in Oncology programmed cell death protein-1 PD-1 locally advanced colorectal cancer neoadjuvant therapy meta-analysis |
| title | The efficacy and safety of neoadjuvant treatment with the PD-1 inhibitor for locally advanced colorectal cancer: a meta-analysis |
| title_full | The efficacy and safety of neoadjuvant treatment with the PD-1 inhibitor for locally advanced colorectal cancer: a meta-analysis |
| title_fullStr | The efficacy and safety of neoadjuvant treatment with the PD-1 inhibitor for locally advanced colorectal cancer: a meta-analysis |
| title_full_unstemmed | The efficacy and safety of neoadjuvant treatment with the PD-1 inhibitor for locally advanced colorectal cancer: a meta-analysis |
| title_short | The efficacy and safety of neoadjuvant treatment with the PD-1 inhibitor for locally advanced colorectal cancer: a meta-analysis |
| title_sort | efficacy and safety of neoadjuvant treatment with the pd 1 inhibitor for locally advanced colorectal cancer a meta analysis |
| topic | programmed cell death protein-1 PD-1 locally advanced colorectal cancer neoadjuvant therapy meta-analysis |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1416943/full |
| work_keys_str_mv | AT yanyu theefficacyandsafetyofneoadjuvanttreatmentwiththepd1inhibitorforlocallyadvancedcolorectalcancerametaanalysis AT yanyu theefficacyandsafetyofneoadjuvanttreatmentwiththepd1inhibitorforlocallyadvancedcolorectalcancerametaanalysis AT linhuang theefficacyandsafetyofneoadjuvanttreatmentwiththepd1inhibitorforlocallyadvancedcolorectalcancerametaanalysis AT linhuang theefficacyandsafetyofneoadjuvanttreatmentwiththepd1inhibitorforlocallyadvancedcolorectalcancerametaanalysis AT rongyan theefficacyandsafetyofneoadjuvanttreatmentwiththepd1inhibitorforlocallyadvancedcolorectalcancerametaanalysis AT rongyan theefficacyandsafetyofneoadjuvanttreatmentwiththepd1inhibitorforlocallyadvancedcolorectalcancerametaanalysis AT minjiang theefficacyandsafetyofneoadjuvanttreatmentwiththepd1inhibitorforlocallyadvancedcolorectalcancerametaanalysis AT minjiang theefficacyandsafetyofneoadjuvanttreatmentwiththepd1inhibitorforlocallyadvancedcolorectalcancerametaanalysis AT shuangjiaoli theefficacyandsafetyofneoadjuvanttreatmentwiththepd1inhibitorforlocallyadvancedcolorectalcancerametaanalysis AT shuangjiaoli theefficacyandsafetyofneoadjuvanttreatmentwiththepd1inhibitorforlocallyadvancedcolorectalcancerametaanalysis AT wangdongfan theefficacyandsafetyofneoadjuvanttreatmentwiththepd1inhibitorforlocallyadvancedcolorectalcancerametaanalysis AT wangdongfan theefficacyandsafetyofneoadjuvanttreatmentwiththepd1inhibitorforlocallyadvancedcolorectalcancerametaanalysis AT yanyu efficacyandsafetyofneoadjuvanttreatmentwiththepd1inhibitorforlocallyadvancedcolorectalcancerametaanalysis AT yanyu efficacyandsafetyofneoadjuvanttreatmentwiththepd1inhibitorforlocallyadvancedcolorectalcancerametaanalysis AT linhuang efficacyandsafetyofneoadjuvanttreatmentwiththepd1inhibitorforlocallyadvancedcolorectalcancerametaanalysis AT linhuang efficacyandsafetyofneoadjuvanttreatmentwiththepd1inhibitorforlocallyadvancedcolorectalcancerametaanalysis AT rongyan efficacyandsafetyofneoadjuvanttreatmentwiththepd1inhibitorforlocallyadvancedcolorectalcancerametaanalysis AT rongyan efficacyandsafetyofneoadjuvanttreatmentwiththepd1inhibitorforlocallyadvancedcolorectalcancerametaanalysis AT minjiang efficacyandsafetyofneoadjuvanttreatmentwiththepd1inhibitorforlocallyadvancedcolorectalcancerametaanalysis AT minjiang efficacyandsafetyofneoadjuvanttreatmentwiththepd1inhibitorforlocallyadvancedcolorectalcancerametaanalysis AT shuangjiaoli efficacyandsafetyofneoadjuvanttreatmentwiththepd1inhibitorforlocallyadvancedcolorectalcancerametaanalysis AT shuangjiaoli efficacyandsafetyofneoadjuvanttreatmentwiththepd1inhibitorforlocallyadvancedcolorectalcancerametaanalysis AT wangdongfan efficacyandsafetyofneoadjuvanttreatmentwiththepd1inhibitorforlocallyadvancedcolorectalcancerametaanalysis AT wangdongfan efficacyandsafetyofneoadjuvanttreatmentwiththepd1inhibitorforlocallyadvancedcolorectalcancerametaanalysis |